Manage Money

Biocon Share Price

NSE Symbol: BIOCON | BSE Code: 532523

NSE

{{stockNseLast}} Volume:{{stockNseVolume}}

Change

Change %

Updated:{{stockUpdatedDateNse}}

BSE

{{stockBseLast}} Volume:{{stockBseVolume}}

Change

Change %

Updated:{{stockUpdatedDateBse}}

Date Open Low High Last Volume
{{date1}} {{open1}} {{low1}} {{high1}} {{last1}} {{volume1}}
{{date2}} {{open2}} {{low2}} {{high2}} {{last2}} {{volume2}}
{{date3}} {{open3}} {{low3}} {{high3}} {{last3}} {{volume3}}
{{date4}} {{open4}} {{low4}} {{high4}} {{last4}} {{volume4}}
{{date5}} {{open5}} {{low5}} {{high5}} {{last5}} {{volume5}}

Live Nifty and Sensex Levels

NIFTY

{{niftyLastValue}}

SENSEX

{{sensexLastValue}}

Get your free Credit report that cost  Rs 1200 for FREE

1. Build your Credit Score

2. Reduce your Current Borrowing / EMI Costs

Biocon Share Price Performance

Biocon Stock Trends - 2018

  • Biocon share price opened in January 2018 at Rs.540.15. After its announcement of the Sandoz deal, the stock price scored a 52-week high as the share price went up to Rs.640 and remained so for a short while. However, the share prices slightly dropped after the Q3 FY18 results were announced and closed the month at Rs.614.90.
  • In February,  the shares were traded at Rs.616 which further went below Rs.600 due to weak global cues. theless, the stocks made a quick recovery and rose to Rs.630 by the end of the month.
  • In March, the market opened for trading with the stock prices at Rs.626.85 which further fell to Rs.571.20 but slightly recovered to Rs.593.90 by the end of the month.
  • The scrip significantly rose over the next month and reached Rs.667.60 by the end of the April.
  • Although the share prices largely fluctuated in May, the closing of the quarter saw the Biocon share price at Rs.674.90.
  • The scrip depreciated considerably in June and after severe fluctuations, ended up at Rs.619.55 during the closing of the month.
  • July was a disastrous month for the investors who had stocks of Biocon, as the share prices drastically fell and sank to Rs.553.30. It recovered slightly and stood at Rs.586.40 at the end of the month.
  • August witnessed a steady increase by more than 40 points to reach Rs.624 at the end of the month.

 Biocon Limited Stock Trends - 2016 and 2017

  • Biocon share price, in the beginning of 2016, was around Rs.170 on both NSE and BSE. it had dropped considerably by the end of February and stood roughly around Rs.150. In March, the company announced a 100% dividend. This announcement, coupled with business developments in the international markets gave a slight push ahead to the share prices.
  • In early April, Biocon's stocks were being traded at roughly around Rs.160. The share price continued to rise steadily in April, May and June up to Rs.246, driven by the company's updates and a highly buoyant market.
  • The price slightly dropped in the initial days of July but after the announcement of the Q1 results and business updates, the company's stocks jumped up to Rs.270 by the end of the month. This upward rising curve continued in August and September when the Biocon share price crossed Rs.300.
  • Biocon released its Q2 FY 2016-17 reports in October. This announcement helped the stocks gain momentum and the share prices hit a new 52-week high. In November, after demonetization, the share price dropped slightly. However, it recovered by December and was roughly around Rs.316 as the year ended.
  • At the beginning of January 2017, Biocon stocks were at around Rs.315. In February, the shares had reached Rs.370 after USFDA accepted the company’s Biologics License Application. The share prices further increased to Rs.379 in March.
  • In April, Biocon stocks hit a record-breaking high after the announcement of bonus issues. However, the share prices fell gradually over May and floated somewhere above Rs.300. Bonus shares were issued in June in a 1:2 ratio. This announcement, coupled with certain other developments, kept the share price steadily above Rs.300.
  • Biocon announced a final dividend of 20% in July, which fuelled the share prices to shoot up above Rs.400. However, due to the poor performance in Q1, the share price fell again. Biocon share prices suffered further in August when the shares fell and floated around Rs.330-Rs.340 and remained so in September too.
  • October witnessed a substantial boost in the share prices, which were being traded at around Rs.370. It crossed the Rs.400 mark in November, backed by positive developments and several updates released by Biocon. This steady rising graph continued in December when the Biocon share price climbed above Rs.500 and closed the year at roughly Rs.537 on NSE and BSE.

Biocon Company Information and Brief History 

Biocon Limited is one of the leading bio-pharmaceutical companies in Asia. It has its headquarters in Bangalore. The company specializes in manufacturing generic APIs which are sold in over 120 countries across the world. These APIs are sold in developed markets of the US and Europe as well. Moreover, the company produces unique biologics and biosimilar products, mostly sold in bulk. Biocon is the largest bio-pharmaceutical company in India that develops medicines for cancer, diabetes and autoimmune disorders at reasonable prices. Biocon share price fluctuates at every moment and thus it is very important for all potential investors to keenly study the performance of the company’s shares before investing in it. 

Get your free Credit report that cost  Rs 1200  for FREE

1. Build your Credit Score

2. Reduce your Current Borrowing / EMI Costs

Timeline

  • Biocon was established in November 1978. During its inception, it had a meager starting capital of Rs.10,000. The company started out as a joint venture between Biocon Biochemicals Ltd., Ireland, and an Indian entrepreneur called Kiran Mazumdar-Shaw. Back in those days, the company mostly manufactured enzymes which were exported to other industries across the world. In 1989, Biocon Biochemicals Limited was acquired by Unilever.
  • As Biocon expanded, it switched its focus from enzymes to biopharmaceuticals. Eventually, Unilever sold its stake in the company and thus Biocon became an independent entity. During the early 1990s, the company established a custom research company called Syngene International Pvt. Ltd. to conduct extensive research in the pharmaceutical sector.
  • Biocon entered the stock markets in 2004 after a highly successful IPO. At the end of its first day, the stocks of Biocon had a market value of around $1.1 billion. Over the years, the company signed pacts with several international entities. Biocon has also come up with many life-saving biosimilars and rare generics that boosted its portfolio. In March 2018 Biocon Limited recorded a market cap of more than Rs.35,000 crore. 

Company’s Wealth and Recent Performance

Biocon Q1 FY 2018-19 Results

  • Biocon reported a 47% rise in its consolidated net profit, at Rs.120 cr for the first quarter of FY 2018-19. This was mainly due to the company's strong performance across various segments. Biocon had posted a net profit of Rs.81 cr during the same quarter in the last fiscal year.
  • The total revenue of the company rose by 21% to reach Rs.1193 cr for this quarter, which was Rs.988 cr during Q1 FY17-18.
  • The robust performance of the company was driven by a 39% rise in research services revenues and a 36% rise in biologics business.
  • Earnings before interest, taxes, depreciation and amortization of Biocon rose by 23.8% y-o-y to reach Rs.237.8 cr. Earlier, the EBITDA margins were at 21.2% as compared to 19.9% that was recorded during Q4 FY17-18 and 20.7% posted in Q1 FY17-18.
  • Biocon's profit after tax also increased by 47.2% y-o-y to reach Rs.119.7 Cr in Q1 FY18-19 as against Rs.81.3 cr during the same quarter in the previous year. 

Biocon FY 2017-18 Annual Report 

  • In the financial year 2017-18, Biocon reported a net profit that declined by 39% to reach Rs.372 cr as against the net profit of Rs.612 cr reported in FY 2016-17.
  • The total revenue in this FY increased by 6% to reach Rs.4336 cr, as against Rs.4079 cr reported in the previous fiscal.
  • The company revealed that the muted performance was mainly due to the continued pricing challenges in the generics business as well as a planned plant shut down. Moreover, the operational expenses of their Malaysian plant impacted the bottom line. 

Biocon Q4 FY18 Results 

  • Biocon reported an increase of around 2% in its net profit for the quarter to reach Rs.130 cr as against Rs.127 cr that was reported in the same period last FY.
  • Biocon’s total revenue in this quarter increased by 27% to reach Rs.1237 cr as against Rs.974 cr that was reported in the same quarter in the previous year.
  • The company's EBITDA also grew by 25% y-o-y, to stand at Rs.233 cr, while the margin was 20% in the same period of FY 2016-17 and 21% in the previous quarter of 2018.
  • The firm reported growth in its profit after tax by 2.3% y-o-y to stand at Rs.130.4 cr.
  • The robust performance in the said quarter was mainly due to the growth in biologics and the research services business. 

Is Investing in Biocon a Good Idea? 

  • Biocon, one of the world's largest bio-pharmaceutical companies, has increased its sales steadily over the years. This resulted in a gradual increase in profit. Furthermore, the company’s share price has also quadrupled since the beginning of 2016 to its present value.
  • Moreover, the company is expanding in terms of capabilities and rapidly capturing the international markets. The company develops generic APIs, which are produced at lower costs and are thus able to maintain the profitability at a much lower price. Over the last two years, USFDA has granted approval to many biologics license applications as well as biosimilars applications submitted by the company. These factors mainly led to the surge in Biocon share price. The rise in the prices is expected to continue in the near future as well.
  • Biocon is has exhibited sound financial performance. The company is highly R&D oriented. Biocon has a publicly listed subsidiary, known as Syngene International Limited. Syngene deals with end-to-end drug discovery, research and development. As the company expands and unfolds its potential, we can expect it to boost its product offerings. Therefore investing in Biocon for long-term may be a viable option. However, it is advisable that all potential investors conduct their own detailed research before investing money.

It is better for all investors to monitor the Biocon share price for a considerable period before deciding to invest in it.

Get your free Credit report that cost  Rs 1200  for FREE

1. Build your Credit Score

2. Reduce your Current Borrowing / EMI Costs

Get your free Credit report that cost  Rs 1200  for FREE

1. Build your Credit Score

2. Reduce your Current Borrowing / EMI Costs